Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (371-380 of 436) with videos related to

Pageof 44
Sort By:
Blood Advances|April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclaxCurtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Blood Cancer Journal|March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyAlex Bataller, Koji Sasaki, Samuel Urrutia, et al.
American Journal of Hematology|November 6, 2020
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Veronica Guerra, et al.
Frontiers in Immunology|February 8, 2021
Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary ComplicationsSang T Kim, Ajay Sheshadri, Vickie Shannon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid MalignanciesJayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Pageof 44

Showing results (371-380 of 436) with videos related to

Sort By:
Pageof 44
Blood Advances|April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclaxCurtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.
Blood Cancer Journal|March 31, 2025
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched studyAlex Bataller, Koji Sasaki, Samuel Urrutia, et al.
American Journal of Hematology|November 6, 2020
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Veronica Guerra, et al.
Frontiers in Immunology|February 8, 2021
Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary ComplicationsSang T Kim, Ajay Sheshadri, Vickie Shannon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid MalignanciesJayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Blood|December 23, 2016
Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumabYasmin Abaza, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Pageof 44